ClinicalTrials.gg
CompletedNCT05924815Updated Dec 19, 2023

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

A Phase 1 interventional study of Aficamten and Aficamten-matching Placebo in Healthy Participants, sponsored by Cytokinetics. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-19.

Sponsored by Cytokinetics · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a single-center, 2-part (Part A and Part B) study in healthy participants. Part A (Dose Finding) is an open-label, SAD study to identify the dose for Part B. Part B (TQT Study) is a randomized, double-blind (with respect to aficamten and matching placebo), positive- and placebo-controlled, single-dose, 3-way crossover study to evaluate the effect of aficamten administration on QT/QTc interval.

02

Conditions studied

  • Healthy Participants

Keywords

  • CK-3773274
  • CK-274
  • Aficamten
03

In context

Lead sponsor

Cytokinetics is the lead sponsor of 41 studies on the registry; 3 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, adult, male or female, 18-45 years of age, inclusive, at the screening visit.
  • Continuous non-smoker who has not used nicotine- and tobacco -containing products for at least 3 months prior to the first dosing based on participant self- reporting.
  • (BMI) ≥ 18.0 and ≤ 30.0 kg/m2 at the screening visit.
  • Medically healthy with no medical history, physical examination, laboratory profiles, and vital signs, as deemed by the PI or designee, including the following:

    • Supine blood pressure is ≥ 90/40 mmHg and ≤ 140/90 mmHg at the screening visit.
    • Oxygen saturation (SpO2) is ≥ 95% at the screening visit.
    • Liver function tests (e.g., , [AST], alanine aminotransferase [ALT]) considered not clinically significant in the opinion of the PI or designee at the screening visit.
    • Estimated ≥ 90 mL/min at the screening visit.
  • No clinically significant history and presence of findings as judged by the PI or designee at the screening visit and first check-in, including each of the following:

    • HR between 50 bpm and 100 bpm, inclusive.
    • interval is ≤450 msec (males) and ≤460 msec (females).
    • QRS ≤110 msec; if >110 msec, result will be confirmed by a manual over read.
    • PR ≤220 msec.
  • ≥65% at the screening visit.

Exclusion criteria

Exclusion Criteria:

  • History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
  • History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Part A (Dose Finding Cohort 1): Aficamten 50 mg

    Participants in this arm will receive a single oral dose of 50 mg aficamten.

    Drug: Aficamten

  • Experimental
    Part A (Dose Finding Cohort 2): Aficamten 75 mg

    Participants in this arm will receive a single oral dose up to 75 mg aficamten.

    Drug: Aficamten

  • Experimental
    Part A (Dose Finding Cohort 3): Aficamten 100 mg

    Participants in this arm will receive a single oral dose up to 100 mg aficamten.

    Drug: Aficamten

  • Experimental
    Part B (TQT Study): Aficamten

    Participants will receive a single oral dose of aficamten. The dose will be determined based on review of Part A PK parameters, echocardiogram parameters, safety, and tolerability for aficamten.

    Drug: Aficamten

  • Placebo comparator
    Part B (TQT Study): Aficamten-matching Placebo

    Participants in this arm will receive a single oral dose of aficamten-matching placebo.

    Drug: Aficamten-matching Placebo

  • Active comparator
    Part B (TQT Study): Moxifloxacin 400 mg

    Participants will receive a single oral dose of 400 mg moxifloxacin

    Drug: Moxifloxacin

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: To determine the dose for Part B

    To determine the dose for Part B based on Part A PK and safety data.

    Time frame: Baseline to End of Study, up to 8 weeks

  2. Part B: placebo-corrected dQTcF for aficamten

    To evaluate the effect of a single oral dose of aficamten on the QTc interval in healthy participants.

    Time frame: Baseline to End of Study, up to 14.5 weeks

Secondary outcomes

  1. Part B: placebo-corrected dQTcF for moxifloxacin

    To demonstrate assay sensitivity of the study to detect a small QTc effect using moxifloxacin as a positive control in healthy participants.

    Time frame: Baseline to End of Study, up to 14.5 weeks

07

Study locations

1 site
  • Celerion, Inc 2420
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Nov 2023, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2023
First posted
Jun 29, 2023
StartActual
May 15, 2023
Primary completionActual
Nov 14, 2023
CompletionActual
Nov 14, 2023
Last update
Dec 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05924815
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
Jun 29, 2023
Start date
May 15, 2023
Primary completion
Nov 14, 2023
Completion
Nov 14, 2023
Last update
Dec 19, 2023

Study contacts

Cytokinetics, MD
study director · Cytokinetics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aficamten

Start the discussion